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ABSTRACT
Objective: To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in
multiple biological functions including immune modulation, in CNS autoimmune demyelinating
disease.
Methods: We investigated the expression of PK2 in mice with experimental autoimmune encephalo-
myelitis (EAE), the animal model of multiple sclerosis (MS), and in patients with relapsing-remitting
MS. We evaluated the biological effects of PK2 on expression of EAE and on development of T-cell
response against myelin by blocking PK2 in vivo with PK2 receptor antagonists. We treated with
PK2 immune cells activated against myelin antigen to explore the immune-modulating effects of this
peptide in vitro.
Results: Pk2 messenger RNA was upregulated in spinal cord and lymph node cells (LNCs) of mice
with EAE. PK2 protein was expressed in EAE inflammatory infiltrates and was increased in sera
during EAE. In patients with relapsing-remitting MS, transcripts for PK2 were significantly
increased in peripheral blood mononuclear cells compared with healthy controls, and PK2 serum
concentrations were significantly higher. A PK2 receptor antagonist prevented or attenuated
established EAE in chronic and relapsing-remitting models, reduced CNS inflammation and demy-
elination, and decreased the production of interferon (IFN)-g and interleukin (IL)-17A cytokines in
LNCs while increasing IL-10. PK2 in vitro increased IFN-g and IL-17A and reduced IL-10 in
splenocytes activated against myelin antigen.
Conclusion: These data suggest that PK2 is a critical immune regulator in CNS autoimmune
demyelination and may represent a new target for therapy. Neurol Neuroimmunol Neuroinflamm
2015;2:e95; doi: 10.1212/NXI.0000000000000095
GLOSSARY
DMSO 5 dimethyl sulfoxide; EAE 5 experimental autoimmune encephalomyelitis; G-CSF 5 granulocyte colony-stimulating
factor; IFN 5 interferon; IL 5 interleukin; LNC 5 lymph node cell; MOG 5 myelin oligodendrocyte glycoprotein; mRNA 5
messenger RNA; MS 5 multiple sclerosis; PBMC 5 peripheral blood mononuclear cells; PBS 5 phosphate-buffered saline;
PK2 5 prokineticin 2; PKR 5 PK receptor; PKR1 5 PK receptor 1; PKR2 5 PK receptor 2; PLP 5 proteolipid protein; qRT-
PCR 5 quantitative real-time PCR; Th 5 T helper cell; TNF 5 tumor necrosis factor.
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the CNS characterized by
demyelination and neurodegeneration. CD41 T lymphocytes activated against myelin autoan-
tigens secreting T helper cell (Th) 1 cytokines and interleukin (IL)-17 are regarded as critical for
initiation and perpetuation of inflammation in MS and its animal model, experimental auto-
immune encephalomyelitis (EAE).1,2 Although immune-modulating therapies can reduce
relapse rate and time to disease progression, there are currently no definitive cures for MS.3 A
better understanding of the pathobiology of this complex disease is crucial in order to develop
better therapies.
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Prokineticin 2 (PK2) is a bioactive peptide
member of the prokineticin family, which com-
prises 2 small secreted proteins (8–12 kDa)
highly conserved across species, namely proki-
neticin 1 (also known as endocrine gland vascu-
lar endothelial factor) and PK2 (also known as
Bv8).4,5 PK2 regulates multiple biological func-
tions including circadian rhythm,6 angiogene-
sis,7,8 neurogenesis of olfactory bulb,9 neuronal
survival,10 reproduction,11 and inflammation.12,13
It activates 2 similar G protein–coupled recep-
tors, PK receptor 1 (PKR1) and PK receptor 2
(PKR2).14 Many cells and tissues, including the
CNS and the immune system, express
PK2.10,15,16 PK2 and PKRs are expressed by bone
marrow cells and circulating leukocytes.4,8,17,18
PK2 was shown to induce hematopoietic cell
mobilization and differentiation.8,18 PK2 in-
creases in inflamed tissues5,15,19 and promotes
inflammation.5,12,13 Moreover, PK2 promotes a
Th1 phenotype by increasing the secretion of
IL-1b and IL-12 and reducing the secretion of
IL-10 in mouse macrophages,13 and decreasing
the production of IL-10 and IL-4 in mouse
splenocytes.12
In this study, we investigated the potential
role of PK2 in CNS autoimmunity.
METHODS EAE induction and assessment. Chronic EAE
was induced in C57BL/6 mice with myelin oligodendrocyte gly-
coprotein (MOG)35–55 peptide, as described.20 Relapsing-
remitting EAE was induced in SJL/J mice, as described.21 All
mice were female and 8–12 weeks old (Charles River
Laboratories, Calco, Italy). Animals were assessed daily for
clinical signs of EAE.21 During pharmacologic studies,
experimenters were blinded to the treatment regimen.
Human samples. Blood samples were obtained from 24 Euro-
pean adults who were diagnosed with relapsing-remitting MS
according to McDonald criteria22 (11 women and 13 men;
mean age 34.7 6 1.7 years; Expanded Disability Status Scale
score 1.7 6 1.4; disease duration 7.9 6 6.9 years, range 19–51
years). Patients were clinically stable, had not started any
immune-modulating therapy before blood collection, and did
not have other acute or chronic inflammatory disorders.
Sampling was performed at least 4 weeks after the last clinical
attack or steroid treatment. Twenty-four individuals (12 women
and 12 men; age 33.7 6 2.1 years, range 23–57 years) who had
no acute or chronic inf lammatory diseases or autoimmune
disorders were included as controls.
Study approval. All procedures involving animals were
approved by the Ethical Committee of the Neurological Institute
Foundation Carlo Besta and by the Italian General Direction for
Animal Health at the Ministry for Health. The study on human
samples was approved by the Ethical Committee of the San Raf-
faele Scientific Institute. Patients and controls gave their written
informed consent.
Treatments. The triazinic derivatives PKR1-preferential
antagonists PC723 and PC124 and the amphibian ortholog of
PK2, Bv8,5,12,13 were used in the study. For in vivo use, PC7
and PC1 were diluted in phosphate-buffered saline (PBS) 1%
dimethyl sulfoxide (DMSO) in a final volume of 100 mL. As a
control, mice were treated with an equal volume of PBS 1%
DMSO (vehicle). Bv8 was isolated from skin secretions of the
frog Bombina variegata as previously described5 and purified to
98% as assessed by high-performance liquid chromatography.
Immunohistochemistry studies. For PK2 and PKR tissue
detection, 5-mm spinal cord sections from snap frozen fresh tis-
sues embedded in optimal cutting temperature compound were
stained with rabbit anti-PK2 (1:200 dilution, Covalab,
Villeurbanne, France) and rabbit anti-PKR1 and anti-PKR2
(1:200 dilution, Alomone, Jerusalem, Israel).25 As negative
controls, we used preadsorption of primary antibodies with
PK2 (Covalab, 1:2), PKR1, and PKR2 (Alomone, 1:10)
peptides, following manufacturer’s instructions. All antibodies
were revealed with EnVision1 rabbit horseradish peroxidase
labeled polymer system and 3,39-diaminobenzidine as a
chromogen according to the manufacturer’s protocol (Dako,
Glostrup, Denmark). Sections were counterstained with
hematoxylin.
Statistical analysis. Unless otherwise specified, results are ex-
pressed as mean 6 SEM. Statistical analyses were performed
using GraphPad Prism software (La Jolla, CA). For EAE scores,
differences between groups were examined for statistical signifi-
cance by the nonparametric analysis Mann–WhitneyU test. In all
other cases, 2-tailed unpaired Student t test was used to detect
differences between independent groups. p Values of,0.05 were
considered statistically significant.
Information on RNA extraction and real-time PCR for PK2,
PKR1, and PKR2; measurement of PK2 and granulocyte colony-
stimulating factor (G-CSF) on serum samples; pathologic studies,
proliferation assay, and cytokine analysis by ELISA; in vitro treat-
ment with PK2/Bv8; and additional details on PC7 and PC1
compounds can be found in the supplemental material at
Neurology.org/nn.
RESULTS PK2 expression increases in the CNS during
chronic EAE. We first evaluated whether the expres-
sion of PK2 was increased in the target organ, the
CNS, during EAE. We used quantitative real-time
PCR (qRT-PCR) to investigate the messenger RNA
(mRNA) expression of Pk2 and its receptors in spinal
cords of C57BL/6 mice with MOG35–55-induced
chronic EAE and naive mice. Pk2 expression was
significantly increased in spinal cords obtained from
mice with EAE compared with naive control mice
(figure 1A). Both Pkr1 and Pkr2 mRNA were
expressed in spinal cords of naive mice, and their
expression did not change significantly in mice with
EAE compared with naive mice. We next wanted to
verify whether PK2 expression was increased in the
CNS of EAE mice at the protein level. We then
performed immunohistochemistry studies using anti-
PK2 antibody. As expected,10,25 in naive mice, PK2
was expressed in neurons of the olfactory bulb and
spinal cord gray matter (figure 1B). In spinal cord
white matter of naive mice, only a weak PK2
2 Neurology: Neuroimmunology & Neuroinflammation
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Figure 1 PK2 increases during EAE
(A) Quantitative real-time RT-PCR (qRT-PCR) analysis to determine relative messenger RNA (mRNA) expression of Pk2,
Pkr1, and Pkr2 in spinal cords of C57BL/6 mice with chronic experimental autoimmune encephalomyelitis (EAE) 14 days
after immunization with myelin oligodendrocyte glycoprotein35–55 or naive mice (n5 5 mice per group). Data are expressed
as percentage of the housekeeping gene Gapdh. Each dot represents an individual mouse and horizontal lines indicate
means. **p , 0.01 by Student t test. (B) Prokineticin 2 (PK2) staining in olfactory bulb (upper panel) and spinal cord gray
matter (middle panel) of naive mice. Preabsorption of anti-PK2 antibody with PK2 peptide inhibited PK2 staining in spinal
cord gray matter neurons (control staining, lower panel). Scale bars 5 50 mm. (C) Representative immunohistochemical
staining of PK2, PK receptor 1 (PKR1), and PK receptor 2 (PKR2) as well as control stainings (preabsorption with PK2, PKR1,
or PKR2 peptides, respectively) in spinal cord white matter of naive mice and in inflammatory infiltrates of EAE mice. Scale
bars 5 50 mm. (D, E) qRT-PCR analysis of mRNA expression levels of Pk2, Pkr1, and Pkr2 in lymph node cells pooled from
naive mice (n 5 14) or mice with chronic EAE at different time points (n 5 4–5 for each time point) (priming, 7 days after
immunization; onset, 9–11 days after immunization; acute, 16 days after immunization). Data are representative of 1 of 2
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staining was detected on glial cells (figure 1C, upper
left panel). In contrast, in spinal cord white matter of
mice with EAE, staining revealed that PK2 was highly
expressed within inflammatory infiltrates (figure 1C,
upper middle panel). Staining for PKR1 and PKR2,
which was absent in spinal cord white matter of naive
mice, was detected in inflammatory infiltrates in mice
with EAE (figure 1C, middle and lower panels). These
results show that inflammatory EAE infiltrates in the
CNS express both PK2 and the receptors for PK2.
PK2 increases in lymph node cells and sera of mice with
EAE. Lymph nodes are known to play a pivotal role in
the development of EAE by acting as a site for prim-
ing of T cells targeting CNS self-antigens. We
evaluated mRNA expression of Pk2 in lymph node
cells (LNCs) of naive mice and mice with EAE.
Transcripts for Pk2 were undetectable in LNCs of
naive mice. However, Pk2 expression increased in
LNCs during EAE (figure 1D). The receptors for
PK2 were both expressed at the mRNA level in
naive LNCs. While the expression of Pkr1 did not
change in LNCs during EAE, Pkr2 expression was
dramatically reduced (figure 1E).
PK2 is a secreted protein. Because Pk2mRNA was
increased in LNCs of mice with EAE, we measured
PK2 protein in serum by ELISA. We observed a sig-
nificant increase of PK2 in sera of mice with EAE
compared with naive mice (about a 2-fold increase
at EAE onset) (figure 1F). G-CSF is a major inducer
of PK2 in vitro and in vivo in both mice and humans,
and treatment with G-CSF increases PK2 in
serum.8,18 We therefore measured G-CSF in sera of
mice with EAE and found a significant increase of
G-CSF during the disease compared with naive mice
(figure 1F). In particular, G-CSF concentrations
peaked during the priming phase of EAE (7 days after
immunization) and remained elevated during disease.
Thus, the increase of G-CSF preceded that of PK2.
PK2 is increased in patients with relapsing-remitting MS.
To determine whether these findings could be poten-
tially relevant to the human disease, we also analyzed
PK2 mRNA expression in peripheral blood mononu-
clear cells (PBMC) from patients with relapsing-
remitting MS and healthy controls by qRT-PCR. To
limit variations in the gene expression, all patients were
clinically stable and none of them had started any
immunomodulatory therapy before sampling. PK2
transcripts were significantly increased in PBMC of
patients with relapsing-remitting MS compared with
healthy controls (figure 2A). We next evaluated the
serum concentrations of PK2 by ELISA and found
that PK2 was significantly increased in sera of
patients with relapsing-remitting MS compared with
healthy controls (figure 2B).
PKR antagonist reduces disease severity and CNS
pathology in chronic and relapsing-remitting EAE. We
next set out to investigate the potential role of PK2
in CNS demyelinating disease by pharmacologic
interference with PK2 receptors. Among the 2 known
receptors for PK2, it was suggested that PKR1 is more
important with regard to the proinflammatory effects
induced by PK2 on immune cells in mice.5,12,13 In
EAE studies, we used the nonpeptidic triazinic com-
pound PC7 (figure 3A), which is a small molecule
that competes for the binding of PK2 to its receptors,
preferentially PKR1, and inhibits the ability of PK2
to activate downstream pathways.23,24 PC7 has a half
maximal inhibitory concentration of 566 12 nM for
PKR1 and 5,230 6 700 nM for PKR2 (figure 3B).
We treated mice with MOG35–55-induced chronic
EAE with daily intraperitoneal injections of PC7
(0.5 mg/kg/day) or vehicle. Treatment with PC7
started on the day of immunization (preventive treat-
ment) significantly delayed the onset of EAE clinical
signs and reduced the severity of the disease (figure
3C and table e-1). In line with the observed disease
attenuation, histopathology of CNS tissue revealed
reduced inflammation and demyelination in spinal
cord of mice treated with PC7 compared with
vehicle-treated control mice (figure 3D). Next, we
evaluated whether PC7 could reduce neurologic
signs in mice with established EAE (therapeutic
treatment). Treatment with PC7 started at the
onset of EAE inhibited disease progression and
reduced the severity within 4 days of treatment start
and continued to confer protection over the next 2
weeks of treatment (figure 3E and table e-1).
We next examined whether antagonizing PKRs
with PC7 was effective in reducing disease severity
in a different EAE model. In contrast to MOG35–55
peptide, which causes chronic EAE in C57BL/6
mice, proteolipid protein (PLP)139–151 peptide indu-
ces relapsing-remitting EAE in SJL/J mice.21 Treat-
ment with PC7 started at the time of EAE induction
significantly reduced disease severity and CNS
inflammation and demyelination (figure 4, A and B
and table e-1). Moreover, treatment with PC7
independent experiments that gave similar results, each including an equal number of mice, and are expressed as percent-
age of the housekeeping geneGapdh (mean6SD). (F) PK2 and granulocyte colony-stimulating factor (G-CSF) concentration
measured by ELISA in sera collected from naive or chronic EAE mice at different time points, as described in D and E. Data
are pooled from 2 independent experiments that gave similar results, each including 4–5 mice per group, and are shown as
mean 6 SEM. *p , 0.05, **p , 0.01, ***p , 0.0001 by Student t test vs naive mice. N.D. 5 not detectable.
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inhibited disease progression when started at the
onset of neurologic signs (figure 4C and table e-1).
To confirm the results obtained with PC7, we used
another triazinic PKR1-preferential antagonist, PC1,
previously used in vivo in rats to block PK2 and
reduce hyperalgesia in a model of inflammatory
pain.5,24 Treatment with PC1 started at the time of
immunization with PLP139–151 resulted in reduced
disease severity in the relapsing-remitting EAE model
(figure 4D and table e-1).
PKR antagonist modulates Th1 and Th17 responses in
EAE. We next evaluated whether the protective phe-
notype observed in EAE mice treated with the PKR
antagonist PC7 could be explained by an alteration
of T-cell activation and Th regulation. We isolated
LNCs from vehicle-treated and PC7-treated EAE
mice during the priming phase of EAE and
examined the recall response to peptide stimulation
in vitro. In mice with MOG35–55-induced EAE,
LNCs from PC7-treated mice displayed
significantly reduced proliferation in response to
peptide stimulation compared with vehicle-treated
mice (figure 5A). Moreover, in LNCs of PC7-treated
mice, the secretion of proinflammatory cytokines
interferon (IFN)-g, IL-17A, and, to a lesser extent,
tumor necrosis factor (TNF) was significantly reduced,
whereas secretion of the suppressor cytokine IL-10 was
significantly increased compared with vehicle-treated
mice (figure 5A). Of interest, IL-6, known to promote
Th17 polarization, was significantly increased in LNCs
from PC7-treated mice compared with vehicle-treated
controls. Similarly, in PLP139–151-induced relapsing-
remitting EAE, we observed a reduction of immune
cell proliferation and of IFN-g and TNF production
in antigen-stimulated LNCs of EAE mice treated with
PC7 compared with those of vehicle-treated mice (figure
5B). However, in this model, PC7 treatment did not
affect IL-17A production. As in the chronic model, IL-6
and IL-10 were increased in LNCs from PC7-treated
SJL mice. These results demonstrate that antagonizing
PKRs induced an important modulation of
proinflammatory responses against CNS myelin in 2
murine models of EAE. This impairment could
represent an important mechanism by which PC7
treatment reduced EAE severity.
PK2/Bv8 promotes Th1 and Th17 responses in vitro.We
next examined the effects of PK2 in vitro on spleno-
cytes from mice immunized with MOG35–55. We
used Bv8, the amphibian ortholog of PK2 (hereafter
referred to as PK2/Bv8), a potent agonist of PKRs and
widely used to study the effect of PKR activation in
mammals.5,12,13 We isolated splenocytes from
MOG35–55-induced EAE mice during the priming
phase and examined the recall response in vitro.
Treatment with PK2/Bv8 increased immune cell pro-
liferation and secretion of IFN-g and IL-17A and
reduced the production of IL-10 (figure 5C). These
effects were reversed by pretreatment of cells with
PC7 antagonist.
DISCUSSION The bioactive peptide PK2 has
recently been shown to have immune-modulating
properties and to promote inflammation. The
potential role of this peptide in MS and
autoimmune disorders has never been investigated.
We present evidence that supports an important
immune regulatory role for PK2 in CNS
autoimmunity. EAE induction resulted in increased
expression of PK2 in mouse spinal cord at both the
mRNA level and the protein level in white matter
inflammatory infiltrates. This finding is in agreement
with different studies reporting an overexpression of
PK2 in human and rodent inflamed tissues with
different pathologic conditions.5,15,19 This EAE-
associated increase of PK2 was not limited to the
inflamed CNS but was also observed in peripheral
immune cells. Indeed, in lymph nodes, Pk2 mRNA
that was undetectable in naive mice was highly
expressed during EAE. Moreover, PK2 increased in
sera of mice with EAE. In parallel with these results,
we showed that in patients with relapsing-remitting
MS, PK2 mRNA expression was increased in PBMC
and PK2 protein concentration was higher in sera than
in healthy controls. Neutrophils and macrophages are
the major sources of PK2 in the immune system.8,16
In MS and EAE, myeloid cells such as macrophages
are a prominent constituent of CNS inflammatory
infiltrates, and monocytes increase in the
bloodstream right before EAE relapses.26 Thus,
macrophages might be important sources of PK2 in
Figure 2 PK2 is increased in patients with RRMS
(A) Quantitative real-time RT-PCR (qRT-PCR) analysis to determine relative PK2 messenger
RNA expression in peripheral blood mononuclear cells from patients with relapsing-remitting
multiple sclerosis (RRMS) and healthy controls (n 5 24 per group). Data are expressed as
percentage of the housekeeping gene ALG8. (B) PK2 concentrations measured by ELISA in
sera collected from patients with RRMS and healthy controls (n 5 24 per group). In both A
and B, each dot represents an individual and horizontal lines indicate the means. *p , 0.05,
***p 5 0.001 by Student t test.
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EAE and MS. G-CSF is the main inducer of PK2 in
myeloid cells.8,27 We showed that PK2 increases early
in LNCs and in serum during EAE and that G-CSF
serum levels peak rapidly during the priming phase.
These results suggest that G-CSF could play a key
role in promoting PK2 transcription and secretion
during EAE. Of interest, in studies published more
than a decade ago, G-CSF expression in MS lesions
Figure 3 PKR antagonist PC7 reduces the severity of chronic EAE
(A) Chemical structure of the prokineticin receptor (PKR) antagonist PC7. (B) Affinity for PKR1 and PKR2 assayed on mem-
brane preparations from Chinese hamster ovary cells stably transfected with PKR1 or PKR2 (see e-Methods). (C) Treatment
with PC7 given daily intraperitoneally ameliorated myelin oligodendrocyte glycoprotein (MOG)35–55-induced experimental
autoimmune encephalomyelitis (EAE) when started at the time of disease induction (n 5 10 mice per group). Data are
representative of 1 of 3 independent experiments that gave similar results. (D) Hematoxylin & eosin (H&E) and anti–myelin
basic protein (MBP) staining of spinal cord sections from MOG35–55-immunized mice treated with PC7 or vehicle from the
day of immunization visualizing immune cell infiltration and demyelination, respectively (arrows). For the analysis, mice were
sacrificed 36 days after immunization. Scale bars 5 200 mm. The graphs below represent comparative analysis of infil-
trated and demyelinated area (% of total area). Each dot represents an individual mouse and horizontal lines indicate the
means. *p,0.05 by Student t test. (E) Daily treatment with PC7 ameliorates EAEwhen started at the onset of clinical signs
(n 5 10 mice per group). Mice were scored and randomized at the onset of neurologic signs immediately before first
treatment. In C and E, solid lines beneath each panel indicate PC7 treatment. Filled circles, PC7 (0.5 mg/kg); open circles,
vehicle only. Data are shown as mean 6 SEM. The clinical EAE traits for these experiments are reported in table e-1. *p ,
0.05 by Mann–Whitney U test.
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was found to be upregulated in acute lesions by gene
microarray analysis (about 13-fold relative to chronic
silent plaques).28 Furthermore, treatment with G-CSF
induced flares in patients with MS29 and patients with
neuromyelitis optica,30 another demyelinating disease
of the CNS in which inflammatory lesions are rich in
granulocytes. Of note, in EAE, unlike MS, treatment
with G-CSF has been shown to reduce disease
severity.28,31 However, similar paradoxical results
between MS and EAE are also seen with anti-TNF,
for example.3
The increased expression of PK2 that we observed
in EAE andMS suggests that this molecule could play
a role in neuroinflammation. In support of this
hypothesis, we showed that blocking PK2 receptors
with the PKR1-preferential antagonist PC7 inhibited
proinflammatory T-cell responses and reduced neuro-
logic signs and CNS damage in chronic and relapsing
EAE. A second PKR1-preferential antagonist, PC1,
also ameliorated EAE. PK2 has been shown to pro-
mote the production of proinflammatory cytokines
from different immune cells and to modulate T-cell
function by reducing anti-inflammatory cytokine
production while promoting Th1 responses.4,5,12,13,16
The amelioration of EAE induced by PC7 and PC1
could be explained at least in part by an overall
impairment of proinflammatory responses against
CNS myelin in EAE mice treated with PC7. Indeed,
treatment reduced the production of IFN-g in LNCs
and, in chronic EAE, the production of IL-17A,
known to play a crucial role in EAE development
and progression, while increasing production of the
suppressor cytokine IL-10, which is protective in
EAE. In line with these data, we showed that PK2/
Bv8 in vitro increased Th1 and Th17 responses in
splenocytes activated against myelin antigen and
Figure 4 Prokineticin receptor antagonists PC7 and PC1 reduce the severity of relapsing-remitting EAE
(A) Treatment with PC7 given daily intraperitoneally ameliorated proteolipid protein (PLP)139-151-induced experimental autoimmune encephalomyelitis (EAE)
when started at the time of disease induction (n5 9 in PC7 group, n5 10 in vehicle group). (B) Hematoxylin & eosin (H&E) and anti–myelin basic protein (MBP)
staining of spinal cord sections from PLP139-151-immunized mice treated with PC7 or vehicle from the day of immunization visualizing immune cell infil-
tration and demyelination, respectively (arrows). For the analysis, mice were sacrificed 32 days after immunization. Scale bars5 200 mm. The graphs on the
right represent comparative analysis of infiltrated and demyelinated area (% of total area). Each dot represents an individual mouse and horizontal lines
indicate the means. *p, 0.05 by Student t test. (C) PC7 ameliorates EAE when given at the onset of clinical signs (n5 10mice per group). Mice were scored
and randomized at the onset of neurologic signs immediately before first treatment. (D) Treatment with PC1 given daily intraperitoneally ameliorated
PLP139–151-induced EAE when started at the time of disease induction (n 5 10 mice per group). In A, C, and D, solid lines beneath each panel indicate
treatment with PC7 (A, C) or PC1 (D). Filled circles, PC7 (0.5 mg/kg); filled diamonds, PC1 (0.5 mg/kg); open circles, vehicle only. Data are shown as mean 6
SEM and are representative of 1 of 2–4 independent experiments that gave similar results. *p , 0.05 by Mann–Whitney U test. The EAE clinical traits for
these experiments are reported in table e-1.
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reduced IL-10, and these effects were blocked by pre-
treatment with PC7. It is interesting that PK2 has
recently been shown to activate STAT3,32 which is
required for Th17 generation and plays critical roles
in the development of EAE and MS.33 In our study,
PC7 treatment in vivo also resulted in an increase of
IL-6 in LNCs of mice with EAE. This cytokine is
usually considered detrimental in EAE, as it promotes
Th17 responses.34 However, IL-6 can also limit
inflammation35 and exert neuroprotective effects.36,37
Our experiments demonstrated that PC7 antago-
nist importantly modulates autoimmune response
against myelin antigen in peripheral immune cells.
PC7 might also have an effect on CNS immune cells,
such as microglial cells, which express PKRs.15 How-
ever, whether or not PC7 can cross the blood-brain
barrier and enter the CNS parenchyma during EAE
still needs to be ascertained. Moreover, other mecha-
nisms might account for the beneficial role of PC7 in
EAE. In fact, other cells expressing prokineticin and
Figure 5 Effects of prokineticin receptor antagonist and PK2/Bv8 on T-cell response against myelin antigens
Lymph node cell (LNC) recall responses from (A) C57BL/6mice immunized with myelin oligodendrocyte glycoprotein (MOG)35–55 or (B) SJL/J mice immunized
with proteolipid protein (PLP)139-151 treated daily intraperitoneally with PC7 (0.5mg/kg) or vehicle. Treatments were started at the time of disease induction
and LNCs were isolated from draining lymph nodes 7–10 days after immunization (5 mice/group). Filled circles, PC7 (0.5mg/kg); open circles, vehicle only. (C)
Splenocytes isolated from MOG35–55-immunized C57BL/6 mice 7 days after immunization were treated in vitro with prokineticin 2 (PK2)/Bv8 (1029 M) or
with PC7 (1027 M) followed by PK2/Bv8 (1029 M) before restimulation with antigen (50 mg/mL) or medium alone. T-cell proliferation was assessed by [3H]
thymidine incorporation in triplicated cultures. Cytokine production was tested by ELISA in supernatants of parallel cultures. Data are shown as mean 6
SEM and are representative of 1 of 2 consecutive independent experiments that gave similar results. *p, 0.05, **p, 0.01, ***p, 0.001 by Student t test.
EAE 5 experimental autoimmune encephalomyelitis; IFN 5 interferon; IL 5 interleukin; N.D. 5 not detectable; TNF 5 tumor necrosis factor.
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PKRs aside from immune cells might be important
targets of PC7 in EAE. For example, within the CNS,
neurons and astrocytes also express PKRs.15 These
cells also express PK2.15 Hypoxia, reactive oxygen
species, and excitotoxic glutamate, known to play a
crucial role in ischemic brain injury and to contribute
to myelin and axonal damage in MS,38,39 increase Pk2
mRNA in primary cortical cultures.15 Intracerebral
administration of exogenous PK2 increases injury
and immune cell recruitment into the CNS in a rat
model of ischemic injury, and PKR antagonist
reduced ischemic damage.15 Moreover, recent work
demonstrates that peripheral nerve damage induces a
significant increase of PK2 immunoreactivity in sen-
sitive neurons and activated astrocytes in mouse spi-
nal cord.25 Although our results suggest that immune
cells infiltrating the CNS, likely macrophages, are an
important source of PK2 during EAE, we cannot rule
out the possibility that neuronal cells might also be
important sources of PK2 during the disease.
The efficacy of PC7 and PC1 in reducing EAE
severity is consistent with an important role for
PKR1 in EAE but does not exclude a possible role
for PKR2 in the disease, as both antagonists are also
able to block PKR2. Thus, the contribution of each
PKR to the pathogenesis of EAE andMS requires fur-
ther investigation. Moreover, identification of PK2-
producing cells and of their targets expressing PKRs
during EAE and MS seems to be very important in
order to understand the contribution of each mole-
cule to disease pathogenesis. Of note, given the
involvement of PK2 and its receptors in many impor-
tant physiologic processes, extreme caution should be
exercised when proposing PKR antagonists as a possi-
ble treatment for EAE and MS, and potential collat-
eral effects associated with the use of PKR antagonists
should be carefully determined.
In conclusion, our results identify PK2 as an
important mediator of CNS autoimmunity and pro-
vide the basis for further investigation of the role of
PK2 in MS and, potentially, for therapeutic applica-
tion of PKR inhibitors in this disease.
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